<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Tue, 26 Sep 2023 04:09:59 +0000</lastbuilddate>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>From the Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37747995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):798-799. doi: 10.1161/CIRCULATIONAHA.123.066278. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37747995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37747995</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066278>10.1161/CIRCULATIONAHA.123.066278</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37747995</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Tracy Hampton</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>From the Literature</dc:title>
<dc:identifier>pmid:37747995</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066278</dc:identifier>
</item>
<item>
<title>Correction to: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37747957/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 26;148(13):e148. doi: 10.1161/CIR.0000000000001183. Epub 2023 Sep 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37747957/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37747957</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001183>10.1161/CIR.0000000000001183</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37747957</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:37747957</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001183</dc:identifier>
</item>
<item>
<title>cGAMP-Dependent PKG1 Activation in Perspective</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37747956/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 26;148(13):1035-1038. doi: 10.1161/CIRCULATIONAHA.123.066073. Epub 2023 Sep 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37747956/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37747956</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066073>10.1161/CIRCULATIONAHA.123.066073</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37747956</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Ulrich Förstermann</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>cGAMP-Dependent PKG1 Activation in Perspective</dc:title>
<dc:identifier>pmid:37747956</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066073</dc:identifier>
</item>
<item>
<title>Statin Reduces Heart Disease Risk in Patients With HIV</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37747955/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 26;148(13):1053-1054. doi: 10.1161/CIRCULATIONAHA.123.065357. Epub 2023 Sep 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37747955/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37747955</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065357>10.1161/CIRCULATIONAHA.123.065357</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37747955</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Bridget M Kuehn</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Statin Reduces Heart Disease Risk in Patients With HIV</dc:title>
<dc:identifier>pmid:37747955</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065357</dc:identifier>
</item>
<item>
<title>Shifting Power Dynamics in Nation's Capital Create Uncertainty for Medical Research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37747954/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 26;148(13):1055-1056. doi: 10.1161/CIRCULATIONAHA.123.066400. Epub 2023 Sep 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37747954/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37747954</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066400>10.1161/CIRCULATIONAHA.123.066400</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37747954</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Cheryl Pegus</dc:creator>
<dc:creator>John Laughner</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Shifting Power Dynamics in Nation's Capital Create Uncertainty for Medical Research</dc:title>
<dc:identifier>pmid:37747954</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066400</dc:identifier>
</item>
<item>
<title>Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37747953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 26;148(13):1057. doi: 10.1161/CIRCULATIONAHA.123.065198. Epub 2023 Sep 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37747953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37747953</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065198>10.1161/CIRCULATIONAHA.123.065198</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37747953</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jairo Aldana-Bitar</dc:creator>
<dc:creator>Ronald P Karlsberg</dc:creator>
<dc:creator>Matthew J Budoff</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study"</dc:title>
<dc:identifier>pmid:37747953</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065198</dc:identifier>
</item>
<item>
<title>Response by Pérez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37747952/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 26;148(13):1059-1060. doi: 10.1161/CIRCULATIONAHA.123.066276. Epub 2023 Sep 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37747952/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37747952</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066276>10.1161/CIRCULATIONAHA.123.066276</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37747952</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Leopoldo Pérez de Isla</dc:creator>
<dc:creator>Adriana Saltijeral Cerezo</dc:creator>
<dc:creator>Pedro Mata</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Pérez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study"</dc:title>
<dc:identifier>pmid:37747952</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066276</dc:identifier>
</item>
<item>
<title>Expanding the Paradigm for Cardiovascular Palliative Care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37747951/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>Cardiovascular disease (CVD) is the leading cause of death worldwide. Despite medical advances, patients with CVD experience high morbidity and mortality rates, affecting their quality of life and death. Among CVD conditions, palliative care has been studied mostly in patients with heart failure, where palliative care interventions have been associated with improvements in patient-centered outcomes, including quality of life, end-of-life care, and health care use. Although palliative care is now...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 26;148(13):1039-1052. doi: 10.1161/CIRCULATIONAHA.123.063193. Epub 2023 Sep 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular disease (CVD) is the leading cause of death worldwide. Despite medical advances, patients with CVD experience high morbidity and mortality rates, affecting their quality of life and death. Among CVD conditions, palliative care has been studied mostly in patients with heart failure, where palliative care interventions have been associated with improvements in patient-centered outcomes, including quality of life, end-of-life care, and health care use. Although palliative care is now incorporated into the American Heart Association/American College of Cardiology/Heart Failure Society of America guidelines for heart failure, the role of palliative care for non-heart failure CVD remains uncertain. Across all causes of CVD, palliative care can play an important role in all domains of CVD care from initial diagnosis to terminal care. In addition to general cardiovascular palliative care practices applicable to all areas, disease-specific palliative care needs may warrant individualized palliative care models. In this review, we discuss the role of cardiovascular palliative care for ischemic heart disease, valvular disease, arrhythmias, peripheral artery disease, and adult congenital heart disease. Although there are multiple barriers to cardiovascular palliative care, we recommend a framework for studying and developing cardiovascular palliative care models to improve patient-centered goal-concordant care for this underserved patient population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37747951/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37747951</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063193>10.1161/CIRCULATIONAHA.123.063193</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37747951</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Sarah Godfrey</dc:creator>
<dc:creator>James N Kirkpatrick</dc:creator>
<dc:creator>Daniel B Kramer</dc:creator>
<dc:creator>Melanie S Sulistio</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Expanding the Paradigm for Cardiovascular Palliative Care</dc:title>
<dc:identifier>pmid:37747951</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.063193</dc:identifier>
</item>
<item>
<title>Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37747950/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 26;148(13):1058. doi: 10.1161/CIRCULATIONAHA.123.065391. Epub 2023 Sep 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37747950/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37747950</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065391>10.1161/CIRCULATIONAHA.123.065391</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37747950</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Xingqing Long</dc:creator>
<dc:creator>Mingyang Jiang</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study"</dc:title>
<dc:identifier>pmid:37747950</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065391</dc:identifier>
</item>
<item>
<title>Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37746744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Among patients with severe AS, those with T2D demonstrate persistent abnormalities in myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function after AVR; AVR effectively normalizes myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function in patients without T2D.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 25. doi: 10.1161/CIRCULATIONAHA.122.063444. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Type 2 diabetes (T2D) is associated with an increased risk of left ventricular dysfunction after aortic valve replacement (AVR) in patients with severe aortic stenosis (AS). Persistent impairments in myocardial energetics and myocardial blood flow (MBF) may underpin this observation. Using phosphorus magnetic resonance spectroscopy and cardiovascular magnetic resonance, this study tested the hypothesis that patients with severe AS and T2D (AS-T2D) would have impaired myocardial energetics as reflected by the phosphocreatine to ATP ratio (PCr/ATP) and vasodilator stress MBF compared with patients with AS without T2D (AS-noT2D), and that these differences would persist after AVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Ninety-five patients with severe AS without coronary artery disease awaiting AVR (30 AS-T2D and 65 AS-noT2D) were recruited (71 years of age [69, 73]; 34 [37%] women). Thirty demographically matched healthy volunteers (HVs) and 30 patients with T2D without AS (T2D controls) were controls. One month before and 6 months after AVR, cardiac PCr/ATP, adenosine stress MBF, global longitudinal strain, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and 6-minute walk distance were assessed in patients with AS. T2D controls underwent identical assessments at baseline and 6-month follow-up. HVs were assessed once and did not undergo 6-minute walk testing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with HVs, patients with AS (AS-T2D and AS-noT2D combined) showed impairment in PCr/ATP (median [interquartile range]; HVs, 2.15 [1.89, 2.34]; AS, 1.66 [1.56, 1.75]; <i>P</i>&lt;0.0001) and vasodilator stress MBF (HVs, 2.11 mL min g [1.89, 2.34]; AS, 1.54 mL min g [1.41, 1.66]; <i>P</i>&lt;0.0001) before AVR. Before AVR, within the AS group, patients with AS-T2D had worse PCr/ATP (AS-noT2D, 1.74 [1.62, 1.86]; AS-T2D, 1.44 [1.32, 1.56]; <i>P</i>=0.002) and vasodilator stress MBF (AS-noT2D, 1.67 mL min g [1.5, 1.84]; AS-T2D, 1.25 mL min g [1.22, 1.38]; <i>P</i>=0.001) compared with patients with AS-noT2D. Before AVR, patients with AS-T2D also had worse PCr/ATP (AS-T2D, 1.44 [1.30, 1.60]; T2D controls, 1.66 [1.56, 1.75]; <i>P</i>=0.04) and vasodilator stress MBF (AS-T2D, 1.25 mL min g [1.10, 1.41]; T2D controls, 1.54 mL min g [1.41, 1.66]; <i>P</i>=0.001) compared with T2D controls at baseline. After AVR, PCr/ATP normalized in patients with AS-noT2D, whereas patients with AS-T2D showed no improvements (AS-noT2D, 2.11 [1.79, 2.43]; AS-T2D, 1.30 [1.07, 1.53]; <i>P</i>=0.0006). Vasodilator stress MBF improved in both AS groups after AVR, but this remained lower in patients with AS-T2D (AS-noT2D, 1.80 mL min g [1.59, 2.0]; AS-T2D, 1.48 mL min g [1.29, 1.66]; <i>P</i>=0.03). There were no longer differences in PCr/ATP (AS-T2D, 1.44 [1.30, 1.60]; T2D controls, 1.51 [1.34, 1.53]; <i>P</i>=0.12) or vasodilator stress MBF (AS-T2D, 1.48 mL min g [1.29, 1.66]; T2D controls, 1.60 mL min g [1.34, 1.86]; <i>P</i>=0.82) between patients with AS-T2D after AVR and T2D controls at follow-up. Whereas global longitudinal strain, 6-minute walk distance, and NT-proBNP all improved after AVR in patients with AS-noT2D, no improvement in these assessments was observed in patients with AS-T2D.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with severe AS, those with T2D demonstrate persistent abnormalities in myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function after AVR; AVR effectively normalizes myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function in patients without T2D.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37746744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37746744</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063444>10.1161/CIRCULATIONAHA.122.063444</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37746744</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Nicholas Jex</dc:creator>
<dc:creator>John P Greenwood</dc:creator>
<dc:creator>Richard M Cubbon</dc:creator>
<dc:creator>Oliver J Rider</dc:creator>
<dc:creator>Amrit Chowdhary</dc:creator>
<dc:creator>Sharmaine Thirunavukarasu</dc:creator>
<dc:creator>Sindhoora Kotha</dc:creator>
<dc:creator>Marilena Giannoudi</dc:creator>
<dc:creator>Anna McGrane</dc:creator>
<dc:creator>Amanda Maccannell</dc:creator>
<dc:creator>Marcella Conning-Rowland</dc:creator>
<dc:creator>Sam Straw</dc:creator>
<dc:creator>Henry Procter</dc:creator>
<dc:creator>Sotiris Papaspyros</dc:creator>
<dc:creator>Betsy Evans</dc:creator>
<dc:creator>Kalyana Javangula</dc:creator>
<dc:creator>Antonella Ferrara</dc:creator>
<dc:creator>Walid Elmahdy</dc:creator>
<dc:creator>Pankaj Kaul</dc:creator>
<dc:creator>Hui Xue</dc:creator>
<dc:creator>Peter Swoboda</dc:creator>
<dc:creator>Peter Kellman</dc:creator>
<dc:creator>Ladislav Valkovič</dc:creator>
<dc:creator>Lee Roberts</dc:creator>
<dc:creator>David Beech</dc:creator>
<dc:creator>Mark T Kearney</dc:creator>
<dc:creator>Sven Plein</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:creator>Eylem Levelt</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis</dc:title>
<dc:identifier>pmid:37746744</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063444</dc:identifier>
</item>
<item>
<title>Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37746718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These data demonstrate that ICI myocarditis is associated with the expansion of a specific population of IFN-γ-induced inflammatory macrophages and suggest the possibility that IFN-γ blockade may be considered as a treatment option for this devastating condition.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 25. doi: 10.1161/CIRCULATIONAHA.122.062551. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic T-lymphocyte-associated protein 4), have revolutionized cancer management but are associated with devastating immune-related adverse events including myocarditis. The main risk factor for ICI myocarditis is the use of combination PD-1 and CTLA4 inhibition. ICI myocarditis is often fulminant and is pathologically characterized by myocardial infiltration of T lymphocytes and macrophages. Although much has been learned about the role of T-cells in ICI myocarditis, little is understood about the identity, transcriptional diversity, and functions of infiltrating macrophages.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used an established murine ICI myocarditis model (<i>Ctla4</i><sup><i>+/-</i></sup><i>Pdcd1</i><sup><i>-/-</i></sup> mice) to explore the cardiac immune landscape using single-cell RNA-sequencing, immunostaining, flow cytometry, in situ RNA hybridization, molecular imaging, and antibody neutralization studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We observed marked increases in CCR2 (C-C chemokine receptor type 2)<sup>+</sup> monocyte-derived macrophages and CD8<sup>+</sup> T-cells in this model. The macrophage compartment was heterogeneous and displayed marked enrichment in an inflammatory CCR2<sup>+</sup> subpopulation highly expressing <i>Cxcl9</i> (chemokine [C-X-C motif] ligand 9), <i>Cxcl10</i> (chemokine [C-X-C motif] ligand 10), <i>Gbp2b</i> (interferon-induced guanylate-binding protein 2b), and <i>Fcgr4</i> (Fc receptor, IgG, low affinity IV) that originated from CCR2<sup>+</sup> monocytes. It is important that a similar macrophage population expressing <i>CXCL9</i>, <i>CXCL10</i>, and CD16α (human homologue of mouse FcgR4) was expanded in patients with ICI myocarditis. In silico prediction of cell-cell communication suggested interactions between T-cells and <i>Cxcl9</i><sup><i>+</i></sup><i>Cxcl10</i><sup><i>+</i></sup> macrophages by IFN-γ (interferon gamma) and CXCR3 (CXC chemokine receptor 3) signaling pathways. Depleting CD8<sup>+</sup> T-cells, macrophages, and blockade of IFN-γ signaling blunted the expansion of <i>Cxcl9</i><sup><i>+</i></sup><i>Cxcl10</i><sup><i>+</i></sup> macrophages in the heart and attenuated myocarditis, suggesting that this interaction was necessary for disease pathogenesis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These data demonstrate that ICI myocarditis is associated with the expansion of a specific population of IFN-γ-induced inflammatory macrophages and suggest the possibility that IFN-γ blockade may be considered as a treatment option for this devastating condition.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37746718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37746718</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.062551>10.1161/CIRCULATIONAHA.122.062551</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37746718</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Pan Ma</dc:creator>
<dc:creator>Jing Liu</dc:creator>
<dc:creator>Juan Qin</dc:creator>
<dc:creator>Lulu Lai</dc:creator>
<dc:creator>Gyu Seong Heo</dc:creator>
<dc:creator>Hannah Luehmann</dc:creator>
<dc:creator>Deborah Sultan</dc:creator>
<dc:creator>Andrea Bredemeyer</dc:creator>
<dc:creator>Geetika Bajapa</dc:creator>
<dc:creator>Guoshuai Feng</dc:creator>
<dc:creator>Jesus Jimenez</dc:creator>
<dc:creator>Ruijun He</dc:creator>
<dc:creator>Antanisha Parks</dc:creator>
<dc:creator>Junedh Amrute</dc:creator>
<dc:creator>Ana Villanueva</dc:creator>
<dc:creator>Yongjian Liu</dc:creator>
<dc:creator>Chieh-Yu Lin</dc:creator>
<dc:creator>Matthias Mack</dc:creator>
<dc:creator>Kaushik Amancherla</dc:creator>
<dc:creator>Javid Moslehi</dc:creator>
<dc:creator>Kory J Lavine</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis</dc:title>
<dc:identifier>pmid:37746718</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.062551</dc:identifier>
</item>
<item>
<title>Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37746717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In patients with non-ST-segment-elevation myocardial infarction undergoing PCI, procedural anticoagulation with bivalirudin and heparin did not result in significantly different rates of mortality or ischemic events, including stent thrombosis and reinfarction. Bivalirudin reduced serious bleeding compared with heparin arising both from the access site and nonaccess sites.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 25. doi: 10.1161/CIRCULATIONAHA.123.063946. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The benefit:risk profile of bivalirudin versus heparin anticoagulation in patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) is uncertain. Study-level meta-analyses lack granularity to provide conclusive answers. We sought to compare the outcomes of bivalirudin and heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed an individual patient data meta-analysis of patients with non-ST-segment-elevation myocardial infarction in all 5 trials that randomized ≥1000 patients with any myocardial infarction undergoing PCI to bivalirudin versus heparin (MATRIX, VALIDATE-SWEDEHEART, ISAR-REACT 4, ACUITY [Acute Catheterization and Urgent Intervention Triage Strategy], and BRIGHT). The primary effectiveness and safety end points were 30-day all-cause mortality and serious bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 12 155 patients were randomized: 6040 to bivalirudin (52.3% with a post-PCI bivalirudin infusion), and 6115 to heparin (53.2% with planned glycoprotein IIb/IIIa inhibitor use). Thirty-day mortality was not significantly different between bivalirudin and heparin (1.2% versus 1.1%; adjusted odds ratio, 1.24 [95% CI, 0.86-1.79]; <i>P</i>=0.25). Cardiac mortality, reinfarction, and stent thrombosis rates were also not significantly different. Bivalirudin reduced serious bleeding (both access site-related and non-access site-related) compared with heparin (3.3% versus 5.5%; adjusted odds ratio, 0.59; 95% CI, 0.48-0.72; <i>P</i>&lt;0.0001). Outcomes were consistent regardless of use of a post-PCI bivalirudin infusion or routine lycoprotein IIb/IIIa inhibitor use with heparin and during 1-year follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with non-ST-segment-elevation myocardial infarction undergoing PCI, procedural anticoagulation with bivalirudin and heparin did not result in significantly different rates of mortality or ischemic events, including stent thrombosis and reinfarction. Bivalirudin reduced serious bleeding compared with heparin arising both from the access site and nonaccess sites.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37746717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37746717</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063946>10.1161/CIRCULATIONAHA.123.063946</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37746717</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:creator>David Erlinge</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Adnan Kastrati</dc:creator>
<dc:creator>Yaling Han</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Rod H Stables</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Stefan K James</dc:creator>
<dc:creator>Enrico Frigoli</dc:creator>
<dc:creator>Patrick Goldstein</dc:creator>
<dc:creator>Yi Li</dc:creator>
<dc:creator>Adeel Shahzad</dc:creator>
<dc:creator>Stefanie Schüpke</dc:creator>
<dc:creator>Ghazaleh Mehdipoor</dc:creator>
<dc:creator>Shmuel Chen</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Aaron Crowley</dc:creator>
<dc:creator>Zhipeng Zhou</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials</dc:title>
<dc:identifier>pmid:37746717</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.063946</dc:identifier>
</item>
<item>
<title>Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37746692/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Combination candesartan and carvedilol therapy had no demonstrable cardioprotective effect in patients receiving anthracycline-based chemotherapy with high-risk on-treatment cardiac troponin I concentrations. Low-risk nonrandomized patients had similar declines in left ventricular ejection fraction, bringing into question the utility of routine cardiac troponin monitoring. Furthermore, the modest declines in left ventricular ejection fraction suggest that the value and clinical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 25. doi: 10.1161/CIRCULATIONAHA.123.064274. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Anthracycline-induced cardiotoxicity has a variable incidence, and the development of left ventricular dysfunction is preceded by elevations in cardiac troponin concentrations. Beta-adrenergic receptor blocker and renin-angiotensin system inhibitor therapies have been associated with modest cardioprotective effects in unselected patients receiving anthracycline chemotherapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a multicenter, prospective, randomized, open-label, blinded end-point trial, patients with breast cancer and non-Hodgkin lymphoma receiving anthracycline chemotherapy underwent serial high-sensitivity cardiac troponin testing and cardiac magnetic resonance imaging before and 6 months after anthracycline treatment. Patients at high risk of cardiotoxicity (cardiac troponin I concentrations in the upper tertile during chemotherapy) were randomized to standard care plus cardioprotection (combination carvedilol and candesartan therapy) or standard care alone. The primary outcome was adjusted change in left ventricular ejection fraction at 6 months. In low-risk nonrandomized patients with cardiac troponin I concentrations in the lower 2 tertiles, we hypothesized the absence of a 6-month change in left ventricular ejection fraction and tested for equivalence of ±2%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between October 2017 and June 2021, 175 patients (mean age, 53 years; 87% female; 71% with breast cancer) were recruited. Patients randomized to cardioprotection (n=29) or standard care (n=28) had left ventricular ejection fractions of 69.4±7.4% and 69.1±6.1% at baseline and 65.7±6.6% and 64.9±5.9% 6 months after completion of chemotherapy, respectively. After adjustment for age, pretreatment left ventricular ejection fraction, and planned anthracycline dose, the estimated mean difference in 6-month left ventricular ejection fraction between the cardioprotection and standard care groups was -0.37% (95% CI, -3.59% to 2.85%; <i>P</i>=0.82). In low-risk nonrandomized patients, baseline and 6-month left ventricular ejection fractions were 69.3±5.7% and 66.4±6.3%, respectively: estimated mean difference, 2.87% (95% CI, 1.63%-4.10%; <i>P</i>=0.92, not equivalent).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Combination candesartan and carvedilol therapy had no demonstrable cardioprotective effect in patients receiving anthracycline-based chemotherapy with high-risk on-treatment cardiac troponin I concentrations. Low-risk nonrandomized patients had similar declines in left ventricular ejection fraction, bringing into question the utility of routine cardiac troponin monitoring. Furthermore, the modest declines in left ventricular ejection fraction suggest that the value and clinical impact of early cardioprotection therapy need to be better defined in patients receiving high-dose anthracycline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://doi.org/10.1186/ISRCTN24439460; Unique identifier, ISRCTN24439460. URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000896-99; Unique identifier: EudraCT 2017-000896-99.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37746692/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37746692</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064274>10.1161/CIRCULATIONAHA.123.064274</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37746692</guid>
<pubDate>Mon, 25 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Peter A Henriksen</dc:creator>
<dc:creator>Peter Hall</dc:creator>
<dc:creator>Iain R MacPherson</dc:creator>
<dc:creator>Shruti S Joshi</dc:creator>
<dc:creator>Trisha Singh</dc:creator>
<dc:creator>Morag Maclean</dc:creator>
<dc:creator>Steff Lewis</dc:creator>
<dc:creator>Aryelly Rodriguez</dc:creator>
<dc:creator>Alex Fletcher</dc:creator>
<dc:creator>Russell J Everett</dc:creator>
<dc:creator>Harriet Stavert</dc:creator>
<dc:creator>Angus Broom</dc:creator>
<dc:creator>Lois Eddie</dc:creator>
<dc:creator>Lorraine Primrose</dc:creator>
<dc:creator>Heather McVicars</dc:creator>
<dc:creator>Pam McKay</dc:creator>
<dc:creator>Annabel Borley</dc:creator>
<dc:creator>Clare Rowntree</dc:creator>
<dc:creator>Simon Lord</dc:creator>
<dc:creator>Graham Collins</dc:creator>
<dc:creator>John Radford</dc:creator>
<dc:creator>Amy Guppy</dc:creator>
<dc:creator>Michelle C Williams</dc:creator>
<dc:creator>Alan Japp</dc:creator>
<dc:creator>John R Payne</dc:creator>
<dc:creator>David E Newby</dc:creator>
<dc:creator>Nick L Mills</dc:creator>
<dc:creator>Olga Oikonomidou</dc:creator>
<dc:creator>Ninian N Lang</dc:creator>
<dc:date>2023-09-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial</dc:title>
<dc:identifier>pmid:37746692</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064274</dc:identifier>
</item>
<item>
<title>Correction to: Managing mental well-being and the emotional aspects of cardiovascular disease: views from the patient lounge</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37742083/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 22:ehad589. doi: 10.1093/eurheartj/ehad589. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37742083/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37742083</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad589>10.1093/eurheartj/ehad589</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37742083</guid>
<pubDate>Sun, 24 Sep 2023 06:00:00 -0400</pubDate>
<dc:date>2023-09-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Managing mental well-being and the emotional aspects of cardiovascular disease: views from the patient lounge</dc:title>
<dc:identifier>pmid:37742083</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad589</dc:identifier>
</item>
<item>
<title>Amyloplast sedimentation repolarizes LAZYs to achieve gravity sensing in plants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37741279/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>Gravity controls directional growth of plants, and the classical starch-statolith hypothesis proposed more than a century ago postulates that amyloplast sedimentation in specialized cells initiates gravity sensing, but the molecular mechanism remains uncharacterized. The LAZY proteins are known as key regulators of gravitropism, and lazy mutants show striking gravitropic defects. Here, we report that gravistimulation by reorientation triggers mitogen-activated protein kinase (MAPK)...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 20:S0092-8674(23)01035-8. doi: 10.1016/j.cell.2023.09.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Gravity controls directional growth of plants, and the classical starch-statolith hypothesis proposed more than a century ago postulates that amyloplast sedimentation in specialized cells initiates gravity sensing, but the molecular mechanism remains uncharacterized. The LAZY proteins are known as key regulators of gravitropism, and lazy mutants show striking gravitropic defects. Here, we report that gravistimulation by reorientation triggers mitogen-activated protein kinase (MAPK) signaling-mediated phosphorylation of Arabidopsis LAZY proteins basally polarized in root columella cells. Phosphorylation of LAZY increases its interaction with several translocons at the outer envelope membrane of chloroplasts (TOC) proteins on the surface of amyloplasts, facilitating enrichment of LAZY proteins on amyloplasts. Amyloplast sedimentation subsequently guides LAZY to relocate to the new lower side of the plasma membrane in columella cells, where LAZY induces asymmetrical auxin distribution and root differential growth. Together, this study provides a molecular interpretation for the starch-statolith hypothesis: the organelle-movement-triggered molecular polarity formation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37741279/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37741279</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.014>10.1016/j.cell.2023.09.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37741279</guid>
<pubDate>Sat, 23 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jiayue Chen</dc:creator>
<dc:creator>Renbo Yu</dc:creator>
<dc:creator>Na Li</dc:creator>
<dc:creator>Zhaoguo Deng</dc:creator>
<dc:creator>Xinxin Zhang</dc:creator>
<dc:creator>Yaran Zhao</dc:creator>
<dc:creator>Chengfu Qu</dc:creator>
<dc:creator>Yanfang Yuan</dc:creator>
<dc:creator>Zhexian Pan</dc:creator>
<dc:creator>Yangyang Zhou</dc:creator>
<dc:creator>Kunlun Li</dc:creator>
<dc:creator>Jiajun Wang</dc:creator>
<dc:creator>Zhiren Chen</dc:creator>
<dc:creator>Xiaoyi Wang</dc:creator>
<dc:creator>Xiaolian Wang</dc:creator>
<dc:creator>Shu-Nan He</dc:creator>
<dc:creator>Juan Dong</dc:creator>
<dc:creator>Xing Wang Deng</dc:creator>
<dc:creator>Haodong Chen</dc:creator>
<dc:date>2023-09-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Amyloplast sedimentation repolarizes LAZYs to achieve gravity sensing in plants</dc:title>
<dc:identifier>pmid:37741279</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.014</dc:identifier>
</item>
<item>
<title>'Paravalvular leak' after Bentall's procedure, yet not a paravalvular leak</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37740945/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 23:ehad607. doi: 10.1093/eurheartj/ehad607. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37740945/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37740945</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad607>10.1093/eurheartj/ehad607</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37740945</guid>
<pubDate>Sat, 23 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Mohammed Idhrees</dc:creator>
<dc:creator>Arun Kumar</dc:creator>
<dc:creator>Bashi Velayudhan</dc:creator>
<dc:date>2023-09-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>'Paravalvular leak' after Bentall's procedure, yet not a paravalvular leak</dc:title>
<dc:identifier>pmid:37740945</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad607</dc:identifier>
</item>
<item>
<title>Long QT syndrome induced by cervical spondylosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37740436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 22:ehad608. doi: 10.1093/eurheartj/ehad608. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37740436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37740436</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad608>10.1093/eurheartj/ehad608</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37740436</guid>
<pubDate>Sat, 23 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>En Li</dc:creator>
<dc:creator>Chaowu Yan</dc:creator>
<dc:creator>Xiaoyu Yang</dc:creator>
<dc:date>2023-09-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Long QT syndrome induced by cervical spondylosis</dc:title>
<dc:identifier>pmid:37740436</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad608</dc:identifier>
</item>
<item>
<title>Surgical pericardiotomy to treat heart failure with preserved ejection fraction: a first clinical study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37740430/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 22:ehad620. doi: 10.1093/eurheartj/ehad620. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37740430/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37740430</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad620>10.1093/eurheartj/ehad620</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37740430</guid>
<pubDate>Sat, 23 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Hartzell V Schaff</dc:creator>
<dc:creator>Samuel J Asirvatham</dc:creator>
<dc:creator>Katlyn E Koepp</dc:creator>
<dc:creator>William J Mauermann</dc:creator>
<dc:creator>Phillip G Rowse</dc:creator>
<dc:date>2023-09-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Surgical pericardiotomy to treat heart failure with preserved ejection fraction: a first clinical study</dc:title>
<dc:identifier>pmid:37740430</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad620</dc:identifier>
</item>
<item>
<title>SARS-CoV-2 variants evolve convergent strategies to remodel the host response</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37738970/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>SARS-CoV-2 variants of concern (VOCs) emerged during the COVID-19 pandemic. Here, we used unbiased systems approaches to study the host-selective forces driving VOC evolution. We discovered that VOCs evolved convergent strategies to remodel the host by modulating viral RNA and protein levels, altering viral and host protein phosphorylation, and rewiring virus-host protein-protein interactions. Integrative computational analyses revealed that although Alpha, Beta, Gamma, and Delta ultimately...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 19:S0092-8674(23)00915-7. doi: 10.1016/j.cell.2023.08.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">SARS-CoV-2 variants of concern (VOCs) emerged during the COVID-19 pandemic. Here, we used unbiased systems approaches to study the host-selective forces driving VOC evolution. We discovered that VOCs evolved convergent strategies to remodel the host by modulating viral RNA and protein levels, altering viral and host protein phosphorylation, and rewiring virus-host protein-protein interactions. Integrative computational analyses revealed that although Alpha, Beta, Gamma, and Delta ultimately converged to suppress interferon-stimulated genes (ISGs), Omicron BA.1 did not. ISG suppression correlated with the expression of viral innate immune antagonist proteins, including Orf6, N, and Orf9b, which we mapped to specific mutations. Later Omicron subvariants BA.4 and BA.5 more potently suppressed innate immunity than early subvariant BA.1, which correlated with Orf6 levels, although muted in BA.4 by a mutation that disrupts the Orf6-nuclear pore interaction. Our findings suggest that SARS-CoV-2 convergent evolution overcame human adaptive and innate immune barriers, laying the groundwork to tackle future pandemics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37738970/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37738970</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.026>10.1016/j.cell.2023.08.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37738970</guid>
<pubDate>Fri, 22 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Mehdi Bouhaddou</dc:creator>
<dc:creator>Ann-Kathrin Reuschl</dc:creator>
<dc:creator>Benjamin J Polacco</dc:creator>
<dc:creator>Lucy G Thorne</dc:creator>
<dc:creator>Manisha R Ummadi</dc:creator>
<dc:creator>Chengjin Ye</dc:creator>
<dc:creator>Romel Rosales</dc:creator>
<dc:creator>Adrian Pelin</dc:creator>
<dc:creator>Jyoti Batra</dc:creator>
<dc:creator>Gwendolyn M Jang</dc:creator>
<dc:creator>Jiewei Xu</dc:creator>
<dc:creator>Jack M Moen</dc:creator>
<dc:creator>Alicia L Richards</dc:creator>
<dc:creator>Yuan Zhou</dc:creator>
<dc:creator>Bhavya Harjai</dc:creator>
<dc:creator>Erica Stevenson</dc:creator>
<dc:creator>Ajda Rojc</dc:creator>
<dc:creator>Roberta Ragazzini</dc:creator>
<dc:creator>Matthew V X Whelan</dc:creator>
<dc:creator>Wilhelm Furnon</dc:creator>
<dc:creator>Giuditta De Lorenzo</dc:creator>
<dc:creator>Vanessa Cowton</dc:creator>
<dc:creator>Abdullah M Syed</dc:creator>
<dc:creator>Alison Ciling</dc:creator>
<dc:creator>Noa Deutsch</dc:creator>
<dc:creator>Daniel Pirak</dc:creator>
<dc:creator>Giulia Dowgier</dc:creator>
<dc:creator>Dejan Mesner</dc:creator>
<dc:creator>Jane L Turner</dc:creator>
<dc:creator>Briana L McGovern</dc:creator>
<dc:creator>M Luis Rodriguez</dc:creator>
<dc:creator>Rocio Leiva-Rebollo</dc:creator>
<dc:creator>Alistair S Dunham</dc:creator>
<dc:creator>Xiaofang Zhong</dc:creator>
<dc:creator>Manon Eckhardt</dc:creator>
<dc:creator>Andrea Fossati</dc:creator>
<dc:creator>Nicholas F Liotta</dc:creator>
<dc:creator>Thomas Kehrer</dc:creator>
<dc:creator>Anastasija Cupic</dc:creator>
<dc:creator>Magdalena Rutkowska</dc:creator>
<dc:creator>Ignacio Mena</dc:creator>
<dc:creator>Sadaf Aslam</dc:creator>
<dc:creator>Alyssa Hoffert</dc:creator>
<dc:creator>Helene Foussard</dc:creator>
<dc:creator>Charles Ochieng' Olwal</dc:creator>
<dc:creator>Weiqing Huang</dc:creator>
<dc:creator>Thomas Zwaka</dc:creator>
<dc:creator>John Pham</dc:creator>
<dc:creator>Molly Lyons</dc:creator>
<dc:creator>Laura Donohue</dc:creator>
<dc:creator>Aliesha Griffin</dc:creator>
<dc:creator>Rebecca Nugent</dc:creator>
<dc:creator>Kevin Holden</dc:creator>
<dc:creator>Robert Deans</dc:creator>
<dc:creator>Pablo Aviles</dc:creator>
<dc:creator>Jose A Lopez-Martin</dc:creator>
<dc:creator>Jose M Jimeno</dc:creator>
<dc:creator>Kirsten Obernier</dc:creator>
<dc:creator>Jacqueline M Fabius</dc:creator>
<dc:creator>Margaret Soucheray</dc:creator>
<dc:creator>Ruth Hüttenhain</dc:creator>
<dc:creator>Irwin Jungreis</dc:creator>
<dc:creator>Manolis Kellis</dc:creator>
<dc:creator>Ignacia Echeverria</dc:creator>
<dc:creator>Kliment Verba</dc:creator>
<dc:creator>Paola Bonfanti</dc:creator>
<dc:creator>Pedro Beltrao</dc:creator>
<dc:creator>Roded Sharan</dc:creator>
<dc:creator>Jennifer A Doudna</dc:creator>
<dc:creator>Luis Martinez-Sobrido</dc:creator>
<dc:creator>Arvind H Patel</dc:creator>
<dc:creator>Massimo Palmarini</dc:creator>
<dc:creator>Lisa Miorin</dc:creator>
<dc:creator>Kris White</dc:creator>
<dc:creator>Danielle L Swaney</dc:creator>
<dc:creator>Adolfo Garcia-Sastre</dc:creator>
<dc:creator>Clare Jolly</dc:creator>
<dc:creator>Lorena Zuliani-Alvarez</dc:creator>
<dc:creator>Greg J Towers</dc:creator>
<dc:creator>Nevan J Krogan</dc:creator>
<dc:date>2023-09-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>SARS-CoV-2 variants evolve convergent strategies to remodel the host response</dc:title>
<dc:identifier>pmid:37738970</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.026</dc:identifier>
</item>
<item>
<title>Can we measurably improve the prediction of recurrent coronary artery disease events?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37738645/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 21;44(36):3466-3468. doi: 10.1093/eurheartj/ehad464.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37738645/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37738645</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad464>10.1093/eurheartj/ehad464</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37738645</guid>
<pubDate>Fri, 22 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>William S Weintraub</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:date>2023-09-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Can we measurably improve the prediction of recurrent coronary artery disease events?</dc:title>
<dc:identifier>pmid:37738645</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad464</dc:identifier>
</item>
<item>
<title>Challenges and opportunities in prognostication: focus on ischaemic heart disease and atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37738644/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230926000957&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 21;44(36):3391-3394. doi: 10.1093/eurheartj/ehad614.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37738644/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230926000957&v=2.17.9.post6+86293ac">37738644</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad614>10.1093/eurheartj/ehad614</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37738644</guid>
<pubDate>Fri, 22 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-09-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Challenges and opportunities in prognostication: focus on ischaemic heart disease and atrial fibrillation</dc:title>
<dc:identifier>pmid:37738644</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad614</dc:identifier>
</item>





























</channel>
</rss>